Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Relmada Therapeutics ( (RLMD) ) is now available.
Relmada Therapeutics announced the termination of its License Agreement with Dr. Charles E. Inturrisi and Dr. Paolo Manfredi concerning the development of esmethadone, effective 90 days after July 7, 2025. This decision ends Relmada’s participation in the esmethadone development program and ceases all material obligations under the agreement, impacting the company’s operational focus and potentially its market positioning in psychiatric treatments.
The most recent analyst rating on (RLMD) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Relmada Therapeutics stock, see the RLMD Stock Forecast page.
Spark’s Take on RLMD Stock
According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.
Relmada Therapeutics’ overall score reflects its high-risk, high-reward profile typical of biotechnology firms in developmental stages. The company’s financial performance is weakened by zero revenue and significant cash burn, tempered by strong cash reserves. Strategic pipeline developments and recent acquisitions offer potential upside, but are countered by challenges such as discontinued projects and reliance on external financing. Technical analysis shows short-term momentum, but the overall outlook remains speculative.
To see Spark’s full report on RLMD stock, click here.
More about Relmada Therapeutics
Relmada Therapeutics operates in the pharmaceutical industry, focusing on the development and commercialization of therapies for central nervous system disorders. The company is involved in the research and development of esmethadone for psychiatric use and other indications.
Average Trading Volume: 1,858,470
Technical Sentiment Signal: Sell
Current Market Cap: $20.25M
See more data about RLMD stock on TipRanks’ Stock Analysis page.